Investigating the role of LSD1 in triple-negative breast cancer and its treatment response
Official title: Role of LSD1 in Triple Negative Breast Cancer Development and Therapeutic Response
Funded at University of Iowa · NIH-11030842 · Data updated 2026-11-12
This study is looking at a protein called LSD1 to see how it affects triple-negative breast cancer and hopes to find new ways to make treatments work better for patients dealing with this tough type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project start | August 15, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $345,700 |
| NIH project number | 5R01CA260357-06 |
| Project ID | NIH-11030842 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who may not respond well to current therapies.
✕Less likely to help
Patients with non-triple-negative breast cancer or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on understanding how LSD1, a protein that regulates gene expression, contributes to the development and treatment resistance of triple-negative breast cancer (TNBC). By examining the mechanisms behind LSD1 overexpression in TNBC, the study aims to identify new therapeutic strategies that could enhance the effectiveness of existing treatments. Patients with TNBC may benefit from insights gained through this research, as it seeks to develop targeted therapies that address the unique challenges of this aggressive cancer subtype.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple-negative breast cancer.
How similar studies have gone: Previous research has shown promising results in targeting epigenetic factors in cancer treatment, suggesting that this approach may yield beneficial outcomes.
Where this research is happening
-
University of Iowa
Iowa City, United States Active
Researchers
- Principal investigator: Huang, Yi — University of Iowa
- Study coordinator: Huang, Yi
Related research
Other NIH-funded projects on the same topics.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Linking heavy metal exposure to a tougher breast cancer type (TNBC)
Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.
-
Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate
Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.
-
Rac-enhanced CAR-Macrophages against TNBC
A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.
-
A new peptide therapy to help treat metastatic triple-negative breast cancer
A new peptide therapy called PEG-FUD is being tested to help treat metastatic triple-negative breast cancer by normalizing the tumor environment to improve treatment delivery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.